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Abstract
Mast cell clonal disorders are characterized by the clonal proliferation of pathological mast
cells as a result of somatic mutations in the KIT gene, most commonly the D816V
mutation. Accumulation and degranulation of these cells causes a wide variety of symp-
toms. Mast cell clonal disorders can be divided into mastocytosis and monoclonal mast cell
activation syndrome, depending of the level of clonality. The severity of mastocytosis
varies from an indolent variant with a good prognosis, to an aggressive condition with
short life expectancy. Diagnosis is based on demonstration of clonality and accumulation
in the skin and in extracutaneous tissues. Treatment is highly individualized, and is based
on the severity of the condition. Treatment of patients with indolent systemic
mastocytosis is aimed at reducing symptoms, using histamine H1 and H2 receptor
antagonists as a starting point. In addition, associated conditions such as osteoporosis
must be treated. Treatment of advanced systemic mastocytosis is aimed at reducing mast
cell load through cytoreductive therapy. The choice of such therapy depends on the KIT
mutational status. Though currently there is no curative treatment available, promising
new therapies such as midostaurin are emerging that have demonstrated success in
reducing symptoms and improving quality of life.
Introduction
Mast cells (MCs) are important effector cells of the
immune system, best known for their role in allergies
and anaphylaxis. They also play an important protective
role, and are involved in wound healing, angiogenesis,
immune tolerance, pathogen defence and blood–brain
barrier function.
MCs are characteristically found surrounding blood
vessels and nerves, but are especially prominent near the
boundaries between the outside world and the internal
milieu, e.g. in the skin, lungs and gastrointestinal tract.
MCs are distinguished by their high content of granules,
containing pro-inflammatory and vasoactive mediators.
MC disorders may involve abnormal reactivity with
normal MC numbers and/or excessive proliferation of
MCs, known as mastocytosis.
Mastocytosis is the most important MC clonal disor-
der. It is a rare condition relevant to many fields of
medicine. The condition is characterized by the clonal
proliferation of pathological MCs. The clinical presenta-
tion is highly heterogeneous. Features of systemic
mastocytosis are caused by the accumulation of clonally
derived MCs in different tissues and by the abnormal
reactivity, causing degranulation of theMC. Proper treat-
ment of this condition is essential and requires a multi-
disciplinary approach. Thus far, there is no curative
treatment for mastocytosis. However, over the last few
years, new methods for treating this condition have
emerged. In this article we review the current views on
the pathophysiologicalmechanisms, classification, diag-
nosis and management of MC clonal disorders.
(Patho)physiology
MCs are immunological cells derived from progenitor cells in the bonemarrow,
whichmature in diverse peripheral tissues [1]. In allergic reactions, activation of
MCs occurs after the MC is exposed to an antigen that cross-links allergen-
specific IgE, which is already bound to the high-affinity Fc epsilon receptor 1
(FcεR1) on the MC. However, they can be activated bymany triggers other than
allergens, such as extreme temperatures and emotional stress [2•].
In normal MCs, stem cell factor (SCF) binds to the CD117 transmembrane
tyrosine kinase receptor, which is encoded by KIT. This receptor regulates MC
growth, migration and survival [2•]. In MC clonal disorders, patients show
somatic mutations in enzyme and receptor genes involved in regulating MC
activity [3]. These mutations cause reduced apoptosis and increased prolifera-
tion of MCs, eventually leading to MC accumulation and easily triggered
activation of MCs [4]. The most common mutation is the D816V mutation in
the tyrosine kinase KIT. Thismutation is detected in up to 90%of adult patients
with systemic mastocytosis, and results in a tyrosine kinase receptor in a
constantly activated state [3, 5].
Clinical presentation
Symptoms in patients with monoclonal MC disorders are caused by the accu-
mulation and degranulation of MCs. MC accumulation results in infiltration of
various tissues, such as the skin and the bone marrow, which may lead to
symptoms such as typical skin lesions in the form of urticaria pigmentosa or
osteolytic lesions in the bone. Degranulation of MCs can cause MC activation
(MCA) [2•]. Systemic MC activation (MCA) is characterized by three main
findings: first, the presence of typical signs and symptoms, e.g. flushing, pruri-
tus, urticaria, nasal congestion and hypotension; second, a substantial and
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transient increase in one or more MC-derived mediators (e.g. tryptase) in
biological fluids after activation; and third, an objective response of symptoms
to treatment with histamine receptor blockers or MC-targeting agents [6].
Classification
Mastocytosis is a clonal MC disorder, and can be subdivided into cutaneous
mastocytosis (CM), systemic mastocytosis (SM) and MC tumours. Criteria for
diagnosing mastocytosis can be found in Table 1. SM may present with or
without cutaneous involvement. In CM, only criteria for mastocytosis in the
skin (MIS) are met. In SM, the major criterion—the presence of multifocal MC
clusters—and one minor criterion, or three minor criteria must be fulfilled.
Minor criteria consist of large proportions of MCs with abnormal morphology,
detection of a D816V KIT mutation, MC expression of CD2 or CD25, and
elevated tryptase levels in the blood.
Adults more often suffer from SM, whereas children mainly suffer from CM.
The typical maculopapular red or brown skin lesions in mastocytosis, urticaria
pigmentosa (UP), are often localized on the thighs, axilla and the lower trunk,
and may spread over a period of years. Mechanical stroking of the lesions
usually produces wheals and reddening, which is known as Darier’s sign [8•].
The skin is involved in approximately 80 % of all mastocytosis cases [9].
Urticaria pigmentosa can be divided into two variants: a monomorphic
variant with small maculopapular lesions, and a polymorphic variant with
larger lesions of variable size and shape. This distinction has important prog-
nostic implications [8•]. The monomorphic variant is typically seen in adult
patients, whereas the polymorphic variant is more often observed in paediatric
patients. Clinical observations suggest that the monomorphic variant in chil-
dren often persists into adulthood, whereas the polymorphic variant may
resolve around puberty. The differences between childhood and adult
mastocytosis are listed in Table 2.
Table 1. SM and MIS criteria, based on Valent et al. [7]
Criteria for systemic mastocytosis
Major Multifocal dense aggregates of 915 MC/cluster in the bone marrow (BM) or in other extracutaneous tissues (EC)
Minor 925 % of MC have an abnormal morphology in BM or are spindle-shaped in EC infiltrates
A KIT mutation at codon 816 in EC, preferably bone marrow
CD 2 and/ or CD25 expression of MC in BM or other EC
Serum tryptase 9 20 ng/mL
The diagnosis SM requires at least 1 major and 1 minor criteria, or 3 minor SM criteria.
Criteria for mastocytosis of the skin (MIS)
Major Typical skin lesions or atypical lesions combined with a positive Dariers’ sign and exclusion of other skin diseases
Minor BMast cell aggregates of 9 15 MC/cluster or monomorphic infiltrate with 9 20 MC per high-power field^
KIT D816V in lesional skin
To diagnose CM at least 1 major and 1 minor MIS criteria are met and the criteria to diagnose SM are not met.
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SM can be subdivided into various forms, the most prevalent being indolent
systemic mastocytosis (ISM), characterized by a low rate of proliferation and a
good prognosis [10]. Smouldering SMand aggressive SM (ASM) aremore severe
and are characterized by B (borderline benign) and C (consider cytoreduction)
findings, respectively. B findings, e.g. tryptase levels higher than 200 ng/mL or
bone marrow infiltration greater than 30 %, indicate organ involvement with-
out dysfunction. C findings, e.g. bone marrow dysfunction or malabsorption
due to GI infiltrates causing weight loss, indicate organ dysfunction [11].
Another variant of SM is SMwith associated clonal haematological non-MC-
lineage disease (SM-AHNMD). MC tumours consist of mast cell leukaemia
(MCL) and mastocytoma. ASM, SM-AHNMD and MCL are also referred to as
advanced systemic mastocytosis, and all have a more aggressive course and a
poorer prognosis [12].
Over the years it has been noted that there are patients with a KIT mutation
who do notmeet the criteria formastocytosis. These patients are classified under
the term monoclonal mast cell activation syndrome (MMAS). MMAS patients
fulfil a maximumof only one or two SMminor criteria. Symptoms ofMMAS are
similar to those of SM, but typical skin lesions are lacking. Treatment of MMAS
is based on the patient’s symptoms; however, the principle of treatment is
comparable to that for patients suffering from ISM.
In summary, monoclonal MC disorders encompass both mastocytosis and
MMAS.
Presentation
The presentation of patients withmastocytosis is heterogeneous. Variation can be
found not only between the various subtypes, due to the different levels of severity
of the condition, but also within subtypes. As mentioned above, symptoms are
caused either by the release of mediators (e.g. anaphylaxis, flushing, abdominal
cramping, pruritus and fatigue) or by MC infiltration (e.g. urticaria pigmentosa,
portal hypertension, hypersplenism and malabsorption). Given the heteroge-
neous presentation, patients may experience little or no inconvenience related
Table 2. Characteristics of typical adulthood-onset and childhood-onset mastocytosis as published by Hartmann et al. [8•]
Adulthood-onset mastocytosis Childhood-onset mastocytosis
Most frequent category of mastocytosis ISM CM
Typical course of the disease Chronic Temporary
Frequency of anaphylaxis (%) 50 G10
Typical tryptase level (μg/l) 920 G20
Typical location of KIT mutation Exon 17, most frequently KIT D816V Exon 8, 9, 11 or 17, or absent
Most frequent type of cutaneous lesions Maculopapular Maculopapular
Typical morphology of maculopapular lesions Monomorphic Polymorphic
Typical size of maculopapular lesions Small Large
Typical distribution of maculopapular lesions Thigh, trunk Trunk, head, extremities
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to their condition, or theymay suffer from symptoms with a high impact on their
quality of life (QoL). Recent studies have validated several QoL questionnaires for
mastocytosis, identifying fatigue and fear of anaphylaxis as the symptoms causing
the greatest inconvenience and impact on patient QoL [13•, 14•].
Anaphylactic reactions are a common feature in mastocytosis, occurring in
approximately half of all patients [15]. Several factors may trigger anaphylactic
reactions, including hymenoptera stings, alcohol consumption, drugs, general
anaesthetics and contrast media. Hymenoptera stings, however, are the most
common trigger for severe, life-threatening anaphylactic reactions, whereas food
and medications generally elicit milder reactions. Approximately 4 % of patients
with a history of hymenoptera sting anaphylaxis (HVAn) have CM or SM [16•].
Patients may develop HVAn at a later stage of their condition. The exact mecha-
nism that evokes HVAn in patients withmastocytosis has not yet been elucidated,
though some studies have identified risk factors for HVAn in mastocytosis pa-
tients. Individuals with a less differentiated gene expression of cells in the periph-
eral blood appear to have a lower risk of HVAn [17]. Dedifferentiated MCs are
more prone to dysfunction, which could explain the finding that higher MC load
reduces the risk of HVAn [18].
Osteoporosis is another common feature in patients with mastocytosis. Oste-
oporosis develops because of both the accumulation and degranulation of MCs
in the bone. This can also lead to osteolytic lesions or even pathological fractures.
The reported prevalence of osteoporosis in ISM patients is high, at 18 to 31 %
[19]. Patients are often male and younger than the general osteoporotic popula-
tion. A high prevalence of pathological fractures, 37 %, has been reported as well
[20••].
Diagnosis
For the detection or exclusion of the criteria for SM, bone marrow
examinations are required. In order to avoid unnecessary bone marrow
biopsies, skin biopsy and measurement of total tryptase in the serum and
histamine metabolites in urine (MH, MIMA) are performed at baseline
and after symptomatic events to assess the probability that SM is present.
A study in which tryptase levels were measured in patients with suspected
ISM showed that tryptase levels lower than 10 μg/L indicated a very low
risk of ISM. The risk of ISM with tryptase levels 910 μg/L is dependent on
the levels of methylhistamine (MH) and methylimidazole acetic acid
(MIMA). If these are elevated, the risk of mastocytosis is high; if not,
the risk is low [21].
If there is an indication for bone marrow examination, bone marrow
biopsies should be examined histologically (e.g. for the presence of oste-
oporosis) and immunohistochemically, stained with antibodies against
tryptase, CD117 and CD25. Bone marrow aspirates should be examined
cytologically, using Wright-Giemsa and toluidine blue staining, and with
flow cytometry. In flow cytometry, cells should be processed within 24 h.
Minimum assessment of CD2, CD25, CD45 and CD117 is recommended.
Unlike normal MCs, the MC of patients with SM express the surface
markers CD2 and/or CD25 [16•]. In addition, KIT mutation analysis
should be performed, especially to detect the presence of a D816V
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mutation. If this mutation is absent, other KIT mutations may be present.
KIT mutation analysis can also be performed in other tissues, but its
sensitivity is highest in the bone marrow [22–24].
Treatment
Treatment of mastocytosis is largely based on experience. Randomized studies
on treatment options are rare, due to the low prevalence of the disease as well as
its heterogeneous clinical presentation.Many therapeutic options are supported
by case reports. Treatment options are highly specific, and applicability in
patients is often dependent on mutational status and clinical features. MC
cannot be eradicated, though cytoreductive therapies can reduce the MC load.
Features in mastocytosis are caused by inappropriate MC activation and
infiltration of MCs in various tissues. Treatment intervention targeting MC
activation consists of three main aspects.
First, patient-specific triggers that may provoke MC activation should be
avoided. Patient tolerability to nonsteroidal anti-inflammatory drugs (NSAIDs)
or opioids should be tested prior to prescription, and if necessary, the use of these
drugs must be avoided. When opioids are indicated, fentanyl is preferred over
morphine [25]. Many anaesthetic agents can trigger MC degranulation and hence
anaphylactic reactions. Therefore, patients withmastocytosis should be regarded as
high-risk patients. Prior to procedures requiring the use of general anaesthesia or
contrast media, patients should be pre-medicated with antihistamines and
glucocorticosteroids. Anaesthesia should be induced preferably by propofol,
etomidate, ketamine, cisatracuriumor pancuronium.Maintenance canbe achieved
by a total intravenous technique or with a volatile anaesthetic such as sevoflurane
[16•]. Several other triggers are known to elicit MC degranulation, including
emotions, stress, alcohol, heat and physical stimuli such as friction or pressure.
Second, if possible, specific trigger treatment should be initiated. Mastocytosis
patients generally have a higher risk of anaphylactic reaction. The life-threatening
nature of anaphylaxis and the impact on QoL from fear of a reaction make the
prevention of anaphylaxis an important aspect of treatment of mastocytosis pa-
tients. It has been recommended that allmastocytosis patients be providedwith an
adrenaline auto-injector. At least two devices should be provided to mastocytosis
patients suffering fromhymenoptera venomanaphylaxis, given the life-threatening
nature of these reactions [26]. In addition, venom immunotherapy (VIT) has been
recommended to reduce the likelihood of anaphylactic reactions. In order for VIT
to be effective in mastocytosis patients, it should be performed as a lifelong
treatment. Furthermore, VIT in mastocytosis is more often accompanied by side
effects than in the general insect venom allergy population [27]. Based on the
natural course of mastocytosis, we question whether VIT should even be consid-
ered in patients with increased IgE levels who have never experienced an allergic
reaction due to hymenoptera stings, since fatal anaphylactic reactions have also
been reported here [28].
Third, treatment to block the release of MCmediators is indicated. These types
of treatment controlMCmediator production aswell as theirmechanismof action.
Treatment is highly individualized. The large heterogeneity in mutational patterns
results in a heterogeneous composition of released mediators and hence a hetero-
geneous clinical presentation. The various symptoms require the appropriate
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therapeutic approach. The advantage of this type of treatment is that it is associated
with relatively few side effects. Unfortunately, its effectiveness is not satisfactory in
all patients.
Therapeutic options can be subdivided into antihistamines, leukotriene antag-
onists, cromoglicic acid systemic glucocorticosteroids, tyrosine kinase inhibitors
(TKIs) and cytoreductive treatment. A combination of drugs is often necessary to
achieve symptom control. An overview of the add-on steps in therapeutic options
can be seen in Fig. 1.
Antihistamines are advised as a starting point in all mastocytosis patients. Even
patientswith no apparent symptomsmay experience an improvement in theirQoL
after administration of antihistamines—for example, improved concentration or
reduced foggy sensation in the head. BothH1 andH2 antihistamines block specific
receptor-mediated symptoms as well asmutual activation of specific MC receptors.
H1R are effective in diminishing symptoms like flushing, pruritus, wheals, swelling
and abdominal cramping, whereas H2R are effective in reducing peptic GI symp-
toms. Second- and third-generation H1 antihistamines are preferred over first-
generation agents because of their less sedating nature. Our personal preference is
levocetirizine, given its minimally sedating character and good clinical response.
Maximum dosage is 20 mg daily, administered in two doses. Ranitidine is a
frequently prescribed H2 antihistamine.
Leukotriene antagonists block the action of leukotrienes. Montelukast, an
antagonist of the cysteinyl leukotriene receptor 1 (Cys-LT1), and zileuton, a 5-
lipoxygenase inhibitor (not available in Europe), are effective in treating
prostaglandin-mediated symptoms such as flushing. They are also effective in
reducing pruritus and musculoskeletal pain. Montelukast has been shown to
reduce symptoms in children as well [29]. Leukotriene antagonists seem to im-
prove the efficacy of H1 and H2 antagonists.
Cromoglicic acid is an MC stabilizer that acts through the G protein-coupled
receptor (GPR)35. It is mainly of use in treating gastrointestinal symptoms, includ-
ing diarrhoea, abdominal cramping, vomiting and meteorism [30]. Gastrointesti-
nal resorption is negligible. A phase II trial evaluating the effects of dispersion
(PA101) in the lungs is currently under way, with results expected by the end of
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Fig. 1. Add-on steps for mastocytosis treatment. Start treatment with H1 antagonists. Add H2 antagonists and/or cromoglicic acid
in the case of GI symptoms or inadequately resolved pruritus. Leukotriene antagonists are added in the case of musculoskeletal pain
or inadequately resolved pruritus. Tyrosine kinase inhibitors are thus far used only in patients with advanced SM.
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Systemic glucocorticosteroids are used in the treatment of acute anaphylactic
reactions and in patients suffering from pulmonary symptoms such as wheezing.
TKIs have been used thus far only in patients with advanced SM. Most have
shown little effectiveness, or their effect has been restricted to a small subgroup of
mastocytosis patients. In the future, they may also be of use in patients with ISM,
though more data on their effectiveness and safety in these patients are needed.
Imatinib therapy was shown to elicit a marked clinical response in patients
without a KIT D816V mutation, but not in patients with a D816V mutation.
Therefore, it is not appropriate for the majority of mastocytosis patients.
Studies on the suitability of dasatinib as a potential treatment option showed
poor results. Masitinib did appear to improve symptoms in some SM patients [4].
A new treatment option is the TKImidostaurin (PKC412), an orally active small
molecule that inhibits multiple kinases, including wild-type and mutant KIT
D816V. Midostaurin was very recently shown to be highly effective in patients
with advanced systemic mastocytosis (SM-AHNMD, ASM, MCL) [32••], with an
overall response rate of 60 %, regardless of subtype. Forty-five percent of patients
demonstrated a major response, meaning complete resolution of at least one type
of mastocytosis-related organ damage, while 15 % showed a partial response. A
phase II study on the effectiveness of midostaurin in patients with ISM is currently
being executed in our centre. Data on symptom improvement are very promising.
Cytoreductive therapies, such as interferon alpha (IFN-α) and cladribine (2-
CdA), are sometimes used as a therapeutic option in advanced systemic
mastocytosis, in light of the aggressive course and poor prognosis of this
disease. In ISM, cytoreductive therapy is not indicated, given the normal life
expectancy of patients and the extensive side effects and mutagenic nature of
cytoreductive drugs [33].
IFN-α and 2-CdA are non-targeted cytoreductive therapies, and have shown
some effect in several studies, especially amongst patients with slowly progressing
ASM. In patients with rapid disease progression, however, IFN-α response was
usually absent. Response to 2-CdA was also limited in rate and duration [34].
In MCL, progression and symptoms may be so severe that allogenic hemato-
poietic cell transplantation (alloHCT) is required. A retrospective study has report-
ed that alloHCTmay be a potentially curative therapeutic option for advanced SM
[35]. This should be done only after debulkingwith polychemotherapy or repeated
cycles of 2-CdA [34].
Hydroxyurea is used as palliative cytoreduction if patients have no response to
polychemotherapy or 2-CdA.
A recent study explored tamoxifen citrate as a cytoreductive treatment option in
ISM patients. Tamoxifen was well tolerated by patients, but it did not reduce their
MC load [36].
Studies are also investigating targets other than KIT, such as the PI3-kinase-AKT
pathway [4]. This has shown positive results in vitro, though no effect has yet been
found in vivo [37].
Treatment options can also be listed per clinical complaint
Recovery from acute anaphylactic reactions is established using epinephrine,
administered as either an intramuscular or an intravenous injection.
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Antihistamines, corticosteroids and omalizumab may have some additional
effect.
Gastrointestinal complaints are treated with H2 antihistamines, cromoglicic
acid, proton pump inhibitors, leukotriene antagonists or ketotifen.
Neurological symptoms may respond to antihistamine treatment.
Cromoglicic acid and ketotifen have also been reported as treatment.
Cardiovascular and pulmonary symptoms are also initially treated with
antihistamines. If this is not sufficient, corticosteroids can be effective. Pulmo-
nary symptoms can be also be treated with leukotriene antagonists, and car-
diovascular symptoms may show improvement on omalizumab.
Naso-ocular symptoms are treated with topical formulations of H1 antihis-
tamines, corticosteroids and cromoglicic acid [38•].
Osteoporosis or other forms of bone involvement are a common feature in
patients with mastocytosis. Osteoporosis is normally treated according to the
guidelines for the general osteoporosis population, which focuses on increasing
bone mineral density (BMD) in order to prevent fractures. Treatment typically
consists of calcium and vitamin D supplements, often complemented with
bisphosphonates, depending on osteoporosis severity and fracture risk. Con-
sidering the differences in pathophysiological mechanisms between
mastocytosis and general osteoporosis, it is questionable whether the mecha-
nismof action of bisphosphonates—increasing BMD—is effective in preventing
fractures in mastocytosis patients. Thus far, the effectiveness of bisphosphonate
treatment has been investigated only in small studies [39•, 40–44]. They have
shown relatively good results, with a low prevalence of fractures and an increase
in BMD during follow-up, but they are limited by low numbers of participants
and/or short follow-up duration. We are currently conducting a larger study on
this subject, with a higher number of participants and a longer follow-up
period.
Since pathological fractures are considered a C-finding in mastocytosis
patients, several studies have reported on the use of cytoreductive therapy,
IFN-α, in these patients [41, 43]. However, osteoporosis is a frequent finding
in ISM patients, and pathological fractures are often reported in such patients
with otherwise low disease activity.Opinions vary onwhether amore aggressive
approach is permissible in these patients, given the high occurrence of side
effects with this type of treatment.
Conclusion and future perspectives
Mast cell clonal disorders are a heterogeneous group of conditions, of which
systemic mastocytosis is most important. Mastocytosis varies in presentation
and severity, making it a relevant condition for multiple fields of medicine and
requiring a multidisciplinary approach. Patients often have a somatic D816V
mutation that causes the accumulation and activation of MCs. Therapy should
be individualized, based on the severity, symptoms, triggers and response to
therapy. Patients with ISM have a good prognosis, and thus cytoreductive
therapy is not indicated. Therapy is aimed at reducing symptoms and treating
secondary conditions such as osteoporosis.
In treating advanced SM, several treatments are available, none of them
curative. The results from the phase II trial of the multikinase inhibitor
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midostaurin are promising with respect to improving symptoms and qual-
ity of life in advanced SM patients. Clinical trials in ISM patients are
currently under way. In addition to drugs targeting KIT, efforts are being
made to develop drugs for alternative targets, which may provide other
treatment options in the future.
Studies investigating differences in genetic composition within subtypes
of mastocytosis may be useful for finding additional treatment options for
mastocytosis, since they may provide us with greater insight into the
emergence of specific symptoms in specific patients.
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